Table 1.
Clinicopathologic Characteristics of patients by treating center. *
| Characteristic | Center 1 (N=49) | Center 2 (N=34) | Center 3 (N=43) | Center 4 (N=45) | P Value |
|---|---|---|---|---|---|
| Median age (range), years | 57 (26-85) | 63 (37-83) | 59 (35-80) | 61 (30-78) | .016 |
| Male | |||||
| Yes | 31 | 10 | 23 | 24 | .023 |
| No | 18 | 24 | 20 | 21 | |
| Primary tumor site | |||||
| Colon | 40 | 22 | 32 | 29 | .21 |
| Rectum | 9 | 12 | 11 | 16 | |
| Positive lymph node primary | |||||
| Yes | 29 | 23 | 24 | 23 | .52 |
| No | 20 | 11 | 19 | 22 | |
| CLM synchronous to primary | |||||
| Yes | 36 | 20 | 26 | 24 | .23 |
| No | 13 | 14 | 17 | 21 | |
| Type of liver resection | |||||
| Major | 26 | 27 | 26 | 14 | <.001 |
| Minor | 23 | 7 | 17 | 31 | |
| Median no. of CLM (range) | 2 (1-11) | 2 (1-4) | 2 (1-13) | 1 (1-7) | .067 |
| Median diameter of the largest CLM (range), cm | 2.5 (0.5-13) | 3 (1-7) | 3 (1-12) | 1.8 (0.3-10) | <.001 |
| Median preoperative CEA level (range), ng/mL | 2.6 (0-859) | 3 (0 - 387) | 17 (0-1640) | 5 (0-153) | <.001 |
| Chemotherapy type† | |||||
| Fluoropyrimidine + oxaliplatin | 5 | 17 | 16 | 0 | <.001 |
| Fluoropyrimidine + irinotecan | 16 | 15 | 9 | 0 | |
| Fluoropyrimidine + oxaliplatin + bev | 24 | 0 | 2 | 40 | |
| Fluoropyrimidine + irinotecan + bev | 2 | 0 | 4 | 3 | |
| Median duration of preoperative CHT (range), months | 2 (1-9) | 3 (1.5-10) | 3 (1-10) | 4.5 (1-10) | <0.001 |
| Recurrence | |||||
| Yes | 33 | 24 | 29 | 28 | .88 |
| No | 16 | 10 | 14 | 17 | |
| Pathologic response | |||||
| Complete | 7 | 1 | 2 | 4 | .08 |
| Major | 19 | 15 | 21 | 29 | |
| Minor | 23 | 18 | 20 | 12 | |
| Tumor thickness at TNI | |||||
| <0.5 mm | 15 | 2 | 9 | 9 | <.001 |
| ≥0.5 mm and <5 mm | 17 | 25 | 20 | 35 | |
| ≥5 mm | 17 | 7 | 14 | 1 |
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; TNI, tumor–normal tissue interface; bev, bevacizumab
*
Values in the table are numbers of patients (percentage) unless otherwise indicated.
†
Patients receiving multiple regimens of preoperative chemotherapy (n=13), only fluropyrimidines (n=4) and cetuximab (n=1) were excluded from this analysis, finally including 153 patients.